Pfizer stock holds steady on 2025 profit and 2026 guidance

Pfizer stock reflects 2025 revenue of $63.6 billion, net income of $8.0 billion, and 2026 adjusted diluted EPS guidance of $2.80 to $3.00.

Pfizer Inc. (US7170811035) anchors Pfizer stock around a 2025 revenue base of $63.6 billion, net income of $8.0 billion, and 2026 adjusted diluted EPS guidance of $2.80 to $3.00. Those figures come from Pfizer's latest annual results and frame the shares as investors wait for the next update from the company.

2025 revenue and profit

In fiscal 2025, Pfizer reported $63.6 billion in revenue and $8.0 billion in net income, according to its annual report. That compares with 2024 revenue of $63.6 billion and net income of $8.0 billion, showing a flat top line and stable bottom line across the year.

The same report showed adjusted diluted EPS of $3.11 for 2025, while the company guided for $2.80 to $3.00 in adjusted diluted EPS for 2026. That guidance range implies a year-over-year step down at the midpoint, and it is the clearest numeric guidepost for Pfizer stock in the current setup.

Guidance sets the tone

Pfizer also reported 2025 adjusted operational revenue of $62.5 billion, which it described as excluding revenues from certain products and reflecting its operating view of the business. The gap between reported revenue of $63.6 billion and adjusted operational revenue of $62.5 billion is modest, but it helps explain how the company frames its internal performance metrics.

For investors, the comparison that matters most is the 2026 EPS range versus the 2025 result. A midpoint of $2.90 would sit 6.8% below the 2025 adjusted diluted EPS of $3.11, which makes earnings execution more important than simple revenue growth in the near term.

What the numbers say

Pfizer's 2025 results also included adjusted cost of sales, adjusted SI&A, and adjusted R&D metrics in the annual report, but the headline story remains the same: a large pharmaceutical base, stable 2025 revenue, and a 2026 earnings range that points to a more measured year. That combination usually keeps attention on pipeline execution, product mix, and margins rather than on any single quarter.

One more dated anchor stands out. Pfizer's annual figures are for fiscal 2025, while the guidance range applies to fiscal 2026, so the market can compare one full year against the next without ambiguity.

Comirnaty still matters

Pfizer's vaccine franchise remains a visible part of the business mix, and Comirnaty is still the best-known product name associated with the company. In the annual results, vaccine and antiviral sales remain part of the broader revenue base, even as the company now relies more heavily on its wider drug portfolio.

That mix matters because product concentration can move profit faster than revenue. A business that clears $63.6 billion in annual revenue but guides to a lower EPS band for 2026 is telling the market that mix, cost, and timing will matter as much as scale.

Stock level and valuation

Pfizer stock can be read against those fiscal 2025 and 2026 figures rather than against a short-lived trading headline. With no live quote inserted here, the most durable market reference in this article is the $63.6 billion 2025 revenue base, the $8.0 billion 2025 net income figure, and the $2.80 to $3.00 2026 EPS guide.

That trio gives the shares a clear numerical frame as of fiscal 2025 and fiscal 2026. The next price reaction, if any, will likely be judged against those same benchmarks.

Pfizer pipeline focus

Paxlovid, Eliquis, and Prevnar remain part of the company's broader commercial mix, but the article's current relevance sits more in the financial frame than in any single product callout. Pfizer's annual report is the main source for the revenue, net income, and EPS numbers that define the stock story here.

The product mix matters because a large-cap drugmaker can post flat revenue and still see earnings shift on cost discipline or portfolio mix. That is why the 2026 EPS guide is more revealing than a generic business profile.

Pfizer stock closes on 2025 base

Pfizer stock remains framed by fiscal 2025 revenue of $63.6 billion, fiscal 2025 net income of $8.0 billion, and fiscal 2026 adjusted diluted EPS guidance of $2.80 to $3.00. Those are the key dated numbers available in the article and the clearest reference points for the next phase of trading.

Pfizer Inc. trades on the NYSE under PFE in USD terms.

Pfizer at a glance

• Company: Pfizer Inc.
• ISIN: US7170811035
• Ticker: NYSE: PFE
• Trading venue: NYSE
• Sector / Industry: Health Care / Pharmaceuticals
• Index membership: S&P 500